2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Each year the National Comprehensive Cancer Network (NCCN) presents the latest updates to its Clinical Practice Guidelines in Oncology, as well as the latest cancer therapies by key opinion leaders.
Each year the National Comprehensive Cancer Network (NCCN) presents the latest updates to its Clinical Practice Guidelines in Oncology, as well as the latest cancer therapies by key opinion leaders. This year’s event, held at The Westin Diplomat in Hollywood, Florida, from March 9-13, 2011, featured two roundtable discussions: (1) “The Many Faces and Challenges of Caregivers” hosted by former ABC newsman Sam Donaldson (to watch the roundtable video in its entirety, go to http://bit.ly/hV6H5x); and (2) “Molecular Testing: Implications for Practice and Policy” hosted by Clifford Goodman, PhD, senior vice president of the Lewin Group.
In addition to the NCCN Guidelines Update sessions and the roundtables, there were other sessions on topics such as hepatitis B screening and chemotherapy, imaging techniques, and radiation oncology. However, it is the NCCN Guidelines Update sessions that generate the most attention and discussion.
According to an NCCN spokeswoman, there were nearly 1800 oncologists, fellows, nurses, pharmacists, and other healthcare professionals at the meeting. In a welcome letter to attendees, William T. McGivney, PhD, the CEO of NCCN, noted that the Clinical Practice Guidelines in Oncology are the “recognized standard for clinical policy in the oncology community.” According to McGivney, the NCCN’s Guidelines cover the treatment of more than 97% of all cancer patients.
A brief summary of the 2011 updates to the NCCN Guidelines are provided below by cancer type.
Stanford Comprehensive Cancer Center Dr Carlson: “Considering there are limited options for women with metastatic breast cancer who have already received other therapies, [eribulin] is a noteworthy treatment option that the Panel felt was important to incorporate into the Guidelines.”
Dana-Farber Cancer Institute
Memorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center Dr Pfister: “Data indicate that HPV presence is associated with an increased risk of oropharynx cancer independent of tobacco or alcohol use.”
University of Texas MD Anderson Cancer Center Dr O’Brien: “For newly diagnosed patients, all three TKIs [tyrosine kinase inhibitors] recommended in the NCCN Guidelines are viable treatment options. Selection of appropriate TKI therapy will depend on the stage of the disease, the agent’s side-effect profile, and its relative effectiveness against BCR-ABL mutations.”
Duke Cancer Institute
Memorial Sloan-Kettering Cancer Center Dr Zelenetz: “Despite recent advances, it remains a major challenge to define indications for preemptive therapies for posttransplant lymphoproliferative disorder and to integrate novel therapeutic approaches with conventional therapies. The NCCN Guidelines now help to provide a solid framework to assist in diagnosis and treatment decisions.”
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Dr Ettinger: “Histology matters in non—small cell lung cancer.”
Fox Chase Cancer Center
Roswell Park Cancer Institute Dr Mohler: “The NCCN Guidelines Panel remains concerned about overdiagnosis and overtreatment of prostate cancer as growing evidence suggests that overtreatment of prostate cancer commits too many men to side effects that outweigh a very small risk of prostate cancer death.”
City of Hope Comprehensive Cancer Center Dr Morgan: “Regardless of the type of cancer, the NCCN Guidelines for Ovarian Cancer reflect the importance of stage and grade of disease on prognosis and treatment recommendations.”